Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

Executive Summary

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.

You may also be interested in...



Pandemic Impact Limited As Chugai Reports Strong First Half

Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel